The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...

UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. The ANCHOR-1 ...

The FDA has accepted GSK’s Biologics License Application for depemokimab as an add-on maintenance treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic rhinosinusitis with nasal polyps (CRSwNP). Tezspire showed numerically ...